At the 2008 Congress of the European League Against Rheumatism (EULAR) in June, the Company presented three-year data from a long-term Phase 2 continuation trial demonstrating that belimumab was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares and potential steroid-sparing activity. It was also generally well tolerated through three years on treatment in combination with standard of care in patients with serologically active SLE. The results confirm and extend the data presented at previous scientific meetings at earlier time points, including a significant reduction in SLE disease activity as measured by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials.
Oncology Products: Initial Data from HGS-ETR1 Multiple Myeloma Trial Expected Third Quarter 2008; Completion of Randomization in HGS-ETR1 NSCLC Trial Expected Shortly; HGS-ETR1 Hepatocellular Cancer Trial and First Clinical Trial of HGS1029 Initiated
Three randomized chemotherapy combination trials of HGS-ETR1 (mapatumumab) are currently underway to evaluate its potential in the treatment of specific cancers. Together, the three trials comprise a critical proof-of-concept phase in the development of HGS-ETR1:
-- HGS expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma.
-- Enrollment is progressing well in the Company's randomized Phase 2
trial of HGS-ETR1 in combination with paclitaxel and carboplatin as
first-line therapy in patients with non-small cell lung cancer (NSCLC). HGS
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved